ACCL1633 - The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Protocol: 
AAAS0470
Phase: 
III

ACCL1633 - The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

This randomized clinical trial is examining how well Lactobacillus plantarum
works in preventing acute graft versus host disease in children who are
undergoing stem cell transplant. Lactobacillus plantarum may help prevent
the development of gastrointestinal graft versus host disease in children,
adolescents, and young adults undergoing donor stem cell transplant.

Are you Eligible? (Inclusion Criteria)

-Between 2 and 25 years of age
-Receiving an stem cell transplant from a donor
-No previous history of stem cell transplant or cellular therapy
-Patients must also meet all other eligibility criteria as outlined in the
study

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States